Rethinking the role of osteopontin in human acute myeloid leukemia

Leuk Lymphoma. 2017 Jun;58(6):1494-1497. doi: 10.1080/10428194.2016.1243682. Epub 2016 Oct 14.

Authors

Annette K Brenner¹, Elise Aasebø², Maria Hernandez-Valladares², Frode Selheim², Frode Berven², Øystein Bruserud^{1

3}

Affiliations

¹ a Section for Hematology, Department of Clinical Science , University of Bergen , Bergen , Norway.
² b Department of Biomedicine , University of Bergen , Bergen , Norway.
³ c Department of Medicine , Haukeland University Hospital , Bergen , Norway.

PMID: 27739925
DOI: 10.1080/10428194.2016.1243682

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Cell Line, Tumor
Cells, Cultured
Combined Modality Therapy
Female
Gene Expression Regulation, Leukemic
Humans
Leukemia, Myeloid, Acute / etiology
Leukemia, Myeloid, Acute / metabolism*
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy
Male
Middle Aged
Mutation
Osteopontin / genetics
Osteopontin / metabolism*
Prognosis
Recurrence
Young Adult

Substances

Biomarkers, Tumor
Osteopontin